Elicit: Mechanism of Adalimumab in TNF-alpha Inhibition
TNF-alpha adalimumab mechanism
Adalimumab neutralizes TNF-alpha through high-affinity binding that blocks receptor interaction, while simultaneously inducing apoptosis in transmembrane TNF-alpha-expressing cells via complement-dependent and caspase-mediated mechanisms and modulating intracellular inflammatory pathways including NF-κB signaling and microRNA networks.
Abstract
Adalimumab functions through five complementary mechanisms to inhibit TNF-alpha activity. Structurally, adalimumab binds TNF-alpha with high affinity (KD 7.05-10 × 10⁻¹¹ M) through a large epitope (2,540 Ų buried surface area) that directly occupies the TNF receptor-binding site, blocking both soluble and transmembrane TNF-alpha. Beyond neutralization, adalimumab induces cytotoxic effects including complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and caspase-3-mediated apoptosis in transmembrane TNF-alpha-expressing cells. Adalimumab modulates intracellular signaling by reversing NF-κB pathway activation and downregulating genes including IKBKB, IRAK1, TRAF2, and MAP3K7, while simultaneously regulating anti-inflammatory microRNAs (miR-1297, miR-30a, miR-126-3p) and pro-inflammatory microRNAs (miR-146a-5p). Cell-type-specific effects include restoration of intracellular TNF-alpha levels in monocytes, CD36 upregulation through NADPH oxidase-mediated redox signaling, suppression of endothelial adhesion molecules, and TNF-RI blockade in osteoclasts.
Methods
We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question.
Paper search
We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of Semantic Scholar and OpenAlex.
Screening
We screened in sources based on their abstracts that met these criteria:
- Mechanistic Focus
- Mechanistic Measurements
- Study Design
- Adalimumab Population
- Mechanistic Investigation
- Adalimumab-Specific Data
- Mechanistic Insights
- Publication Type
Data extraction
We asked a large language model to extract each data column below from each paper:
- Mechanism Category
- Experimental Model
- Key Mechanistic Findings
- Target Cells/Tissues
- Anti-TNF Comparisons
- Clinical Relevance
Results
Characteristics of Included Studies
| Study | Full Text Retrieved? | Experimental Model | Mechanism Category | Disease Context |
|---|---|---|---|---|
| Aleksandra Plata-Babula et al., 2025 | Yes | HaCaT keratinocytes (in vitro) | Binding/neutralization, Cellular regulation | Psoriasis |
| Shi Hu et al., 2013 | Yes | Crystal structure, E. coli and CHO cells (in vitro) | Binding/neutralization (epitope binding, receptor blockade) | TNF-alpha-associated diseases |
| Carlos Zamora-Atenza et al., 2014 | Yes | Primary monocytes from RA patients and healthy controls (in vitro and human) | Binding/neutralization, Cytotoxic effects, Signal transduction, Cellular regulation, Tissue/organ effects | Rheumatoid arthritis |
| Raghav Oberoi et al., 2016 | Yes | THP-1 macrophages, HUVECs, hypercholesterolemic mice (in vitro and in vivo) | Binding/neutralization, Tissue/organ effects | Atherosclerosis, rheumatoid arthritis |
| H. Mitoma et al., 2008 | No | Jurkat T cells (in vitro) | Binding/neutralization, Cytotoxic effects, Signal transduction | Rheumatoid arthritis and inflammatory disorders |
| J. Boyer et al., 2007 | Yes | Primary human monocytes (in vitro) | Signal transduction, Binding/neutralization | Chronic inflammatory diseases, rheumatoid arthritis |
| Shi Hu et al., 2014 | Yes | Structural studies (crystallography) | Binding/neutralization (epitope binding, receptor blockade) | TNF-alpha-associated diseases |
| Chong Shen et al., 2006 | No | THP-1 cells, SCID-Beige mice (in vitro and in vivo) | Binding/neutralization, Cytotoxic effects | Crohn’s disease and rheumatoid arthritis |
| B. Harvey & Z. Kaymakcalan, 2014 | No | Primary human osteoclast precursors (in vitro) | Binding/neutralization (receptor blockade) | TNF-alpha-related conditions |
| F. Prattichizzo et al., 2016 | Yes | HUVECs, MCF-7 cells, CACs from psoriasis patients (in vitro and human) | Binding/neutralization, Cellular regulation, Tissue/organ effects | Psoriasis, endothelial senescence |
Thematic Analysis of Adalimumab Mechanisms
Molecular Binding and TNF-Alpha Sequestration
Cytotoxic Mechanisms
Signal Transduction and Pathway Modulation
NF-κB Pathway Regulation
MAPK Pathway Effects
CD36 and Lipid Metabolism
MicroRNA Modulation
Cellular Regulation and Phenotype Modulation
Monocyte Regulation
Endothelial Function
Osteoclast Inhibition
Comparative Mechanisms Among Anti-TNF Agents
Clinical Implications of Mechanistic Findings
Therapeutic Efficacy Mechanisms
Biomarker Potential
Resistance Mechanisms
Cardiovascular and Bone Protection
Anti-Aging and Cancer-Related Effects
Synthesis
The mechanistic studies reveal adalimumab functions through five complementary mechanisms: (1) direct TNF-alpha sequestration via high-affinity binding to soluble and transmembrane forms, (2) cytotoxic elimination of transmembrane TNF-alpha-expressing cells through CDC, ADCC, and caspase-mediated apoptosis, (3) reverse signaling through transmembrane TNF-alpha inducing cell cycle arrest, (4) modulation of intracellular signaling cascades including NF-κB and MAPK pathways, and (5) epigenetic regulation through microRNA modulation.